WuXi Biologics offers the full spectrum of biological drug discovery services for the generation, selection, characterization and production of high potency, novel antibody therapeutics. We offer seven, integrated antibody discovery platforms for screening and lead identification of monoclonal, bispecific and multispecific abs or other biotherapeutic approaches such as antibody-drug conjugates (ADCs), antibody fragments (e.g., Fabs, scFVs) and Fc-fusion proteins. Based on your R&D goals, we advise and collaborate with you to tailor a program that best suits your technical and budgetary requirements. Each platform you utilize takes advantage of our core competencies:
- World-class research expertise
- State-of-the-art facilities
- Well-established project management systems
- Efficient workflows
- Demonstrated success in generating antibodies against a multitude of targets and identifying candidate antibodies in all disease areas
In addition, we offer novel antibody generation and engineering technology platforms for bispecific (WuXiBody®) and multispecific (SDarBody™) antibodies and antibody-drug conjugates (WuXiDAR4™).
WuXi Biologics offers multiple antibody engineering and generation platforms for the discovery of antibody-based therapeutics